Key result
Direct oral anticoagulants, specifically direct factor Xa inhibitors, are endorsed as first-line treatments for venous thromboembolism, offering fixed dosing but requiring careful consideration of drug interactions and contraindications.
Why the study?
Venous thromboembolism management in Japan has substantially evolved with direct factor Xa inhibitors becoming mainstream, requiring clarification of their distinct clinical characteristics and individual risks and benefits.
Direct factor Xa inhibitors are the mainstream treatment for VTE, offering convenience but requiring careful patient selection and risk-benefit assessment in specific populations such as cancer, antiphospholipid syndrome, and extreme obesity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Satokawa et al. (2022) conducted a review in Venous thromboembolism (VTE). Direct Oral Anticoagulants (DOACs) / Direct Factor Xa Inhibitors vs. Vitamin K antagonists / Low molecular weight heparin was evaluated. Direct oral anticoagulants, specifically direct factor Xa inhibitors, are endorsed as first-line treatments for venous thromboembolism, offering fixed dosing but requiring careful consideration of drug interactions and contraindications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: